secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001534120-26-000026
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics buys option to reduce AlmataBio milestone from $15M to $7.375M
--------------------------------------------------------------------------------

- Pays $2.25M upfront for 90-day option to pay $5.125M (cash/stock) in lieu of $15M Phase 3 dosing milestone.
- If option not exercised, $12.75M milestone remains due upon first patient in Phase 3 trial.
- Agreement amends March 2024 Merger Agreement for AlmataBio acquisition.
- Effective April 26, 2026; option decision due within 90 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/0001534120-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/avtx-20260426.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer